Chronic treatment with the thiazolidinedione, MCC-555, is associated with reductions in nitric oxide synthase activity and β-cell apoptosis in the pancreas of the Zucker Diabetic Fatty rat

International Journal of Experimental Pathology

Volumn 84, Issue 2, 2003, Pages 83-89

  Pickavance, Lucy C ^a   Widdowson, Peter S ^a   Foster, John R ^b   Williams, Gareth ^a   Wilding, John P H ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b JEALOTT S HILL INTERNATIONAL RESEARCH CENTRE   (United Kingdom)

Author keywords

cells; Apoptosis; Diabetes mellitus type 2; Fatty acids; Nitric oxide; Pancreas; Thiazolidinedione; ZDF rats

Indexed keywords

NETOGLITAZONE; NITRATE; NITRIC OXIDE SYNTHASE; NITRITE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOACCUMULATION; CELL ASSAY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INDUCTION; MALE; NICK END LABELING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT; RAT STRAIN;

ANIMALS; APOPTOSIS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; INSULIN; ISLETS OF LANGERHANS; MALE; NITRIC OXIDE SYNTHASE; RATS; RATS, ZUCKER; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0038236522     PISSN: 09599673     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2613.2003.00337.x     Document Type: Article

References (21)

1. BELL G.I. & POLONSKY K.S. (2001) Diabetes mellitus and genetically programmed defects in β-cell function. Nature 414, 788-791.
2. CORBETT J.A., SWEETLAND M.A., WANG J.L., LANCASTER J.R. Jr & MCDANIEL M.L. (1993) Nitric oxide mediates cytokine-induced inhibition of insulin secretion by human islets of Langerhans. Proc. Natl. Acad. Sci. USA 90, 1731-1735.
3. DAWSON V.L., DAWSON T.M., LONDON E.D., BREDT D.S. & SNYDER S.H. (1991) Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc. Natl. Acad. Sci. USA 88, 6368-6371.
4. HARRIS M.I. (1996) Impaired glucose tolerance - prevalence and conversion to NIDDM. Diabetes Med. 13 (Suppl. 2), S9-S11.
5. LEBOVITZ H.E. & BANERJI M.A. (2001) Insulin resistance and its treatment by thiazolidinediones. Recent Progr. Horm. Res. 56, 265-294.
6. LAWRY O.H., ROSEBROUGH N.J., FARR A.L. & RANDALL R.J. (1951) Protein measurements with the Folin phenol reagent. J. Biol. Chem. 93, 265-275.
7. MCDANIEL M.L., KODON G., HILL J.R., MARSHALL J.A. & CORBETT J.A. (1996) Cytokines and nitric oxide in islet inflammation and diabetes. Proc. Soc. Exp. Biol. Med. 211, 24-32.
8. OAKES N.D., CAMILLERI S., FURLER S.M., CHISHOLM D.J. & KRAEGEN E.W. (1997) The insulin sensitizer, BRL 49653, reduces systemic fatty acid supply and utilization and tissue lipid availability in the rat. Metabolism 46, 935-942.
9. OAKES N.D., KENNEDY C.J., JENKINS A.B., LAYBUTT D.R., CHISHOLM D.J. & KRAEGEN E.W. (1994) A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes 43, 1203-1210.
10. OHNEDA M., INMAN L.R. & UNGER R.H. (1995) Caloric restriction in obese prediabetic rats prevents β-cell depletion, loss of β-cell GLUT2 and glucose incompetence. Diabetologia 38, 173-179.
11. PICKAVANCE L., WIDDOWSON P.S., KING P., ISHII S., TANAKA H. & WILLIAMS G. (1998) The development of overt diabetes in young Zucker Diabetic Fatty (ZDF) rats and the effects of chronic MCC-555 treatment. Dr. J. Pharmacol. 125, 767-770.
12. RANDLE P.J. (1998) Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabetes Metab. Rev. 14, 263-283.
13. SALTIEL A.R. & KAHN C.R. (2001) Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414, 799-806.
14. SHIMABUKURO M., KOYAMA K., LEE Y. & UNGER R.H. (1997) Leptin- or troglitazone-induced lipopenia protects islets from interleukin 1β cytotoxicity. J. Clin. Invest. 100, 1750-1754.
15. SHIMABUKURO M., ZHOU Y.-T., LEE Y. & UNGER R.H. (1998) Troglitazone lowers islet fat and restores beta cell function of Zucker Diabetic Fatty rats. J. Biol. Chem. 273, 3547-3550.
16. UNGER R.H. (1997) How obesity causes diabetes in Zucker Diabetic Fatty rats. Trends Endocrinol. Metab. 7, 276-282.
17. UNGER R.H. & ORCI L. (2001) Diseases of liporegulation: new perspective on obesity and related disorders. FASEB J. 15, 312-321.
18. UPTON R., WIDDOWSON P.S., ISHII S., TANAKA H. & WILLIAMS G. (1998) Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555. Br. J. Pharmacol. 125, 1708-1714.
19. WIDDOWSON P.S., FARNWORTH M., DUNN D. & WYATT I. (1996) Evidence that L-2-chloropropionic acid-induced neurotoxicity involves a constitutive nitric oxide synthase. Br. J. Pharmacol. 119, 374-378.
20. YKI-JÄRVINEN H. & WILLIAMS G. (1997) Insulin resistance in noninsulin-dependent diabetes mellitus. In: Textbook of Diabetes, Vol. 1, 2nd edn (Ed. J. PICKUP & G. WILLIAMS). Oxford: Blackwell Science, pp. 1-13.
21. ZIMMET P., ALBERTI K.G.M.M. & SHAW J. (2001) Global and societal implications of the diabetes epidemic. Nature 414, 783-787.